AUD 16.33
(7.65%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|---|
Operating Cash Flow | 98.71 Million | 63.57 Million | -10.22 Million | 91.78 Million | 127.52 Million | -3.08 Million |
Net Income | 50.7 Million | 91.25 Million | 100.71 Million | 88.13 Million | 15.45 Million | 70.28 Million |
Depreciation & Amortization | 9.8 Million | 11.16 Million | 10.51 Million | 10.83 Million | 10.9 Million | 2.25 Million |
Deferred income taxes | - | -132.42 Million | 10.05 Million | -1.92 Million | -10.22 Million | -2.19 Million |
Stock-based compensation | -708 Thousand | 2.01 Million | 4.32 Million | 7 Million | 2.5 Million | 3.14 Million |
Change in working capital | -77.71 Million | -105.92 Million | -163.89 Million | -46.37 Million | -19.59 Million | -53.15 Million |
Other non-cash items | 204.71 Million | 197.92 Million | 28.06 Million | 34.11 Million | 128.49 Million | -23.41 Million |
Investing Cash Flow | -148.76 Million | -164.36 Million | -93.89 Million | -26.84 Million | -82.74 Million | -1.89 Million |
Investments in PPE | -1.46 Million | -1.33 Million | -3.82 Million | -2.78 Million | -3.14 Million | -1.89 Million |
Acquisitions | - | -15.45 Million | - | - | -67.71 Million | - |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | -133 Thousand | -147.58 Million | -90.07 Million | -24.06 Million | -11.88 Million | -2000.00 |
Financing Cash Flow | 20.02 Million | 136.64 Million | 71.53 Million | -52.07 Million | -18.83 Million | 11.67 Million |
Debt repayment | -69.31 Million | -185.14 Million | -128.9 Million | -19.94 Million | -124.38 Million | -229.32 Million |
Dividends payments | -42.17 Million | -40.05 Million | -49.98 Million | -24.22 Million | -39.51 Million | -34.47 Million |
Common Stock Repurchased | - | - | - | - | -27.82 Million | 91.98 Million |
Common Stock Issuance | - | - | - | - | 152.2 Million | 137.34 Million |
Other Financing Activities | -7.11 Million | 361.84 Million | 250.42 Million | -7.9 Million | 20.68 Million | 46.14 Million |
Accounts receivables | -54.57 Million | -113.92 Million | -140.7 Million | -68.03 Million | -13.68 Million | -42.96 Million |
Accounts payables | -14.61 Million | 5.4 Million | -20.03 Million | 11.05 Million | 6.24 Million | -9.15 Million |
Inventory | - | - | - | - | - | - |
Other working capital | -8.52 Million | 2.59 Million | -3.16 Million | 10.6 Million | -12.15 Million | -1.03 Million |
Cash at beginning of period | 58.82 Million | 23.7 Million | 55.67 Million | 48.66 Million | 22.7 Million | 16.01 Million |
Cash at end of period | 27.84 Million | 58.82 Million | 23.7 Million | 55.67 Million | 48.66 Million | 22.7 Million |
Capital Expenditure | -1.46 Million | -1.33 Million | -3.82 Million | -2.78 Million | -3.14 Million | -1.89 Million |
Effect of forex changes on cash | -943 Thousand | 251 Thousand | 606 Thousand | 146 Thousand | - | 1.00 |
Net cash flow / Change in cash | -30.97 Million | 35.11 Million | -31.97 Million | 7.01 Million | 25.95 Million | 6.69 Million |
Free Cash Flow | 97.25 Million | 62.24 Million | -14.04 Million | 89 Million | 124.38 Million | -4.97 Million |
Breakdown | 2024 Q4 | 2024 FY | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | 62.83 Million | 50.7 Million | -12.12 Million | 91.25 Million | 59.42 Million | 31.82 Million |
Depreciation & Amortization | 5.27 Million | 9.8 Million | 5.54 Million | 11.16 Million | 5.58 Million | 5.57 Million |
Deferred income taxes | - | - | - | -132.42 Million | -20.29 Million | - |
Stock-based compensation | -708 Thousand | -708 Thousand | - | 2.01 Million | 2.01 Million | - |
Change in working capital | -497 Thousand | -77.71 Million | -209.89 Million | -105.92 Million | 7.53 Million | -288.35 Million |
Other non-cash items | -89.83 Million | 204.71 Million | -7.98 Million | 197.92 Million | 132.71 Million | -149.23 Million |
Investing Cash Flow | -538 Thousand | -148.76 Million | -927 Thousand | -164.36 Million | -148.19 Million | -16.17 Million |
Investments in PPE | -405 Thousand | -1.46 Million | -927 Thousand | -1.33 Million | -612 Thousand | -718 Thousand |
Acquisitions | - | - | - | -15.45 Million | - | -15.45 Million |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | -133 Thousand | -133 Thousand | - | -147.58 Million | -3000.00 | - |
Financing Cash Flow | 26.83 Million | 20.02 Million | -6.81 Million | 136.64 Million | -26.16 Million | 162.8 Million |
Debt repayment | - | -69.31 Million | -29.79 Million | -185.14 Million | - | -191.45 Million |
Dividends payments | -10.2 Million | -42.17 Million | -31.97 Million | -40.05 Million | -15.64 Million | -24.4 Million |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | 37.04 Million | -7.11 Million | 25.15 Million | 361.84 Million | -10.51 Million | 187.21 Million |
Accounts receivables | - | -54.57 Million | - | -113.92 Million | - | - |
Accounts payables | - | -14.61 Million | - | 5.4 Million | - | - |
Inventory | - | - | - | - | - | - |
Other working capital | -497 Thousand | -8.52 Million | -209.89 Million | 2.59 Million | 7.53 Million | -288.35 Million |
Cash at beginning of period | 31.98 Million | 58.82 Million | 58.82 Million | 23.7 Million | 53.67 Million | 23.7 Million |
Cash at end of period | 27.84 Million | 27.84 Million | 31.98 Million | 58.82 Million | 58.82 Million | 53.67 Million |
Capital Expenditure | -405 Thousand | -1.46 Million | -927 Thousand | -1.33 Million | -612 Thousand | -718 Thousand |
Effect of forex changes on cash | -501 Thousand | -943 Thousand | -442 Thousand | 251 Thousand | -57 Thousand | 308 Thousand |
Net cash flow / Change in cash | -4.13 Million | -30.97 Million | -26.83 Million | 35.11 Million | 5.14 Million | 29.96 Million |
Free Cash Flow | -23.33 Million | 97.25 Million | -26.58 Million | 62.24 Million | 185.94 Million | -123.69 Million |
PCL
600113
GRXMF
IAUFF
ANMOL
CLA